Escitalopram (Standard)

[1]Zhang, P., et al., Structure-activity relationships for a novel series of citalopram (1- (3- (dimethylamino) propyl) -1- (4-fluorophenyl) -1,3-dihydroisobenzofuran-5-carbon itrile) analogues at monoamine transporters. J Med Chem, 2010. 53 (16) : p. 6112-21.|[2]Pastoor, D. and J. Gobburu, Clinical pharmacology review of escitalopram for the treatment of depression. Expert Opin Drug Metab Toxicol, 2014. 10 (1) : p. 121-8.|[3]Wu C , et al. Escitalopram alleviates stress-induced Alzheimer's disease-like tau pathologies and cognitive deficits by reducing hypothalamic-pituitary-adrenal axis reactivity and insulin/GSK-3β signal pathway activity. Neurobiol Aging. 2018;67:137-147.|[4]Cirrito JR, et al. Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model. Neurology. 2020;95 (19) :e2666-e2674.